D. J. Betteridge - Publications, H-index & Citations

D. J. Betteridge

saint michaels hospital toronto

52H指数

249论文数

1.6W被引数

收录论文 46

发表时间

Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes

ATHEROSCLEROSIS

IF5.7

2018-07-01

OAAI

Colombo, Marco; Looker, Helen C.; Farran, Bassam; Agakov, Felix; Brosnan, M. Julia; Welsh, Paul; Sattar, Naveed; Livingstone, Shona; Durrington, Paul N.; Betteridge, D. John; McKeigue, Paul M.; Colhoun, Helen M.

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes 基线ldl-c，收缩压和心血管结局之间的不同预测关系

INTERNATIONAL JOURNAL OF CARDIOLOGY

IF3.2

2016-11-01

OAAI

Deedwania, Prakash C.; Pedersen, Terje R.; DeMicco, David A.; Breazna, Andrei; Betteridge, D. John; Hitman, Graham A.; Durrington, Paul; Neil, Andrew

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

DIABETOLOGIA

IF10.2

2015-11-17

OAAI

Livingstone, Shona J.; Looker, Helen C.; Akbar, Tahira; Betteridge, D. John; Durrington, Paul N.; Hitman, Graham A.; Neil, H. Andrew W.; Fuller, John H.; Colhoun, Helen M.

LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes

DIABETES CARE

IF16.6

2014-05-10

OAAI

Hawa, Mohammed Iqbal; Buchan, Ana Paula; Ola, Thomas; Wun, Chuan Chuan; DeMicco, David A.; Bao, Weihang; Betteridge, D. John; Durrington, Paul N.; Fuller, John H.; Neil, H. Andrew W.; Colhoun, Helen; Leslie, Richard David; Hitman, Graham A.

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients A Meta-Analysis

CIRCULATION

IF38.6

2013-10-01

174

OAAI

Boekholdt, S. Matthijs; Arsenault, Benoit J.; Hovingh, G. Kees; Mora, Samia; Pedersen, Terje R.; LaRosa, John C.; Welch, K. M. A.; Amarenco, Pierre; DeMicco, David A.; Tonkin, Andrew M.; Sullivan, David R.; Kirby, Adrienne; Colhoun, Helen M.; Hitman, Graham A.; Betteridge, D. John; Durrington, Paul N.; Clearfield, Michael B.; Downs, John R.; Gotto, Antonio M., Jr.; Ridker, Paul M.; Kastelein, John J. P.

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)Ldl-c对阿托伐他汀治疗反应的遗传决定因素的全基因组关联研究: Lp(a) 的重要性

JOURNAL OF LIPID RESEARCH

IF4.1

2012-05-01

108

OAAI

Deshmukh, Harshal A.; Colhoun, Helen M.; Johnson, Toby; McKeigue, Paul M.; Betteridge, D. John; Durrington, Paul N.; Fuller, John H.; Livingstone, Shona; Charlton-Menys, Valentine; Neil, Andrew; Poulter, Neil; Sever, Peter; Shields, Denis C.; Stanton, Alice V.; Chatterjee, Aurobindo; Hyde, Craig; Calle, Roberto A.; DeMicco, David A.; Trompet, Stella; Postmus, Iris; Ford, Ian; Jukema, J. Wouter; Caulfield, Mark; Hitman, Graham A.

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes An Analysis From the CARDS Trial

DIABETES

IF7.5

2011-08-20

149

OAAI

Colhoun, Helen M.; Betteridge, D. John; Durrington, Paul; Hitman, Graham; Neil, Andrew; Livingstone, Shona; Charlton-Menys, Valentine; Bao, Weihang; DeMicco, David A.; Preston, Gregory M.; Deshmukh, Harshal; Tan, Kathryn; Fuller, John H.

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

DIABETES OBESITY & METABOLISM

IF5.7

2011-06-21

PREAI

Ferrannini, E.; Betteridge, D. J.; Dormandy, J. A.; Charbonnel, B.; Wilcox, R. G.; Spanheimer, R.; Erdmann, E.; DeFronzo, R. A.; Laakso, M.

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

DIABETES OBESITY & METABOLISM

IF5.7

2011-05-24

PREAI

Leiter, L. A.; Betteridge, D. J.; Farnier, M.; Guyton, J. R.; Lin, J.; Shah, A.; Johnson-Levonas, A. O.; Brudi, P.

Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes

CLINICAL SCIENCE

IF7.7

2010-10-08

PREAI

Tam, Xystus H. L.; Shiu, Sammy W. M.; Leng, Lin; Bucala, Richard; Betteridge, D. John; Tan, Kathryn C. B.

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study

ATHEROSCLEROSIS

IF5.7

2010-08-01

PREAI

Neil, H. A. W.; Cooper, J.; Betteridge, D. J.; Capps, N.; McDowell, I. F. W.; Durrington, P. N.; Seed, M.; Mann, J. I.; Humphries, S. E.

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

DIABETOLOGIA

IF10.2

2010-03-31

OAAI

Schernthaner, G.; Barnett, A. H.; Betteridge, D. J.; Carmena, R.; Ceriello, A.; Charbonnel, B.; Hanefeld, M.; Lehmann, R.; Malecki, M. T.; Nesto, R.; Pirags, V.; Scheen, A.; Seufert, J.; Sjoholm, A.; Tsatsoulis, A.; DeFronzo, R.

Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes 阿托伐他汀对2型糖尿病患者血清可溶性晚期糖基化终产物受体的影响

ATHEROSCLEROSIS

IF5.7

2010-03-01

PREAI

Tam, H. L.; Shiu, S. W. M.; Wong, Y.; Chow, W. S.; Betteridge, D. J.; Tan, K. C. B.

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)

DIABETIC MEDICINE

IF3.4

2009-11-24

OAAI

Scheen, A. J.; Tan, M. H.; Betteridge, D. J.; Birkeland, K.; Schmitz, O.; Charbonnel, B.

Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)

AMERICAN JOURNAL OF KIDNEY DISEASES

IF8.2

2009-11-01

228

PREAI

Colhoun, Helen M.; Betteridge, D. John; Durrington, Paul N.; Hitman, Graham A.; Neil, H. Andrew W.; Livingstone, Shona J.; Charlton-Menys, Valentine; DeMicco, David A.; Fuller, John H.

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)

DIABETIC MEDICINE

IF3.4

2009-09-25

OAAI

Scheen, A. J.; Tan, M. H.; Betteridge, D. J.; Birkeland, K.; Schmitz, O.; Charbonnel, B.

Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apoliproprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

CLINICAL CHEMISTRY

IF6.3

2009-03-01

OAAI

Charlton-Menys, Valentine; Betteridge, D. John; Colhoun, Helen; Fuller, John; France, Michael; Hitman, Graham A.; Livingstone, Shona J.; Neil, H. Andrew W.; Newman, Connie B.; Szarek, Michael; DeMicco, David A.; Durrington, Paul N.

Impact of peripheral arterial disease in patients with diabetes-Results from PROactive (PROactive 11)

ATHEROSCLEROSIS

IF5.7

2009-01-01

PREAI

Dormandy, J. A.; Betteridge, D. J.; Schernthaner, G.; Pirags, V.; Norgren, L.

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

DIABETOLOGIA

IF10.2

2008-10-30

OAAI

Charlton-Menys, V.; Betteridge, D. J.; Colhoun, H.; Fuller, J.; France, M.; Hitman, G. A.; Livingstone, S. J.; Neil, H. A. W.; Newman, C. B.; Szarek, M.; DeMicco, D. A.; Durrington, P. N.

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)

DIABETIC MEDICINE

IF3.4

2007-11-26

PREAI

Hitman, G. A.; Colhoun, H.; Newman, C.; Szarek, M.; Betteridge, D. J.; Durrington, P. N.; Fuller, J.; Livingstone, S.; Neil, H. A. W.

研究方向